Cometa Therapeutics Inc
Publicly observedTowson, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Towson | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Cometa Therapeutics Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | RNTBQE96PX23 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jun 2025Publicly observed
NIH SBIR/STTR award: ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
USD 845,383.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2025Publicly observed
NIH SBIR/STTR award: ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
USD 299,648.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.